SST001, an α-syn PET tracer from Mabwell's incubated company SynuSight Biotech, received NMPA approval to initiate a clinical trial ...Middle East

SHANGHAI, April 14, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that 18F-FD4 (R&D code: SST001), an α-synuclein (α-syn) targeted PET tracer independently developed by its incubated company...

Hence then, the article about sst001 an a syn pet tracer from mabwell s incubated company synusight biotech received nmpa approval to initiate a clinical trial was published today ( Wednesday 15/04/2026 - 03:02 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( SST001, an α-syn PET tracer from Mabwell's incubated company SynuSight Biotech, received NMPA approval to initiate a clinical trial )

Also on site :

• Julie Greenwald and Max Lousada Launch 26.2, a New Label, in Partnership With Sony Music
• Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds
• Protein is having its moment, but how much do you actually need?